background
bronchiectasi
guidelin
recommend
antibiot
treatment
acut
respiratori
exacerb
randomis
placebocontrol
trial
children
lack
hypothesis
oral
amoxicillinclavulan
azithromycin
would
superior
placebo
achiev
symptom
resolut
nonsever
exacerb
children
day
treatment
method
multicentr
threearm
parallel
doubledummi
doubleblind
randomis
placebocontrol
trial
four
paediatr
centr
australia
new
zealand
enrol
children
age
year
ctconfirm
bronchiectasi
unrel
cystic
fibrosi
care
respiratori
physician
least
two
respiratori
exacerb
month
studi
entri
particip
alloc
exacerb
onset
receiv
oral
suspens
amoxicillinclavulan
mgkg
per
day
plu
placebo
azithromycin
azithromycin
mgkg
per
day
plu
placebo
amoxicillinclavulan
placebo
day
independ
statistician
prepar
computergener
permutedblock
size
randomis
sequenc
stratifi
centr
age
caus
particip
caregiv
studi
coordin
investig
mask
treatment
assign
data
analysi
complet
primari
outcom
proport
children
exacerb
resolut
day
intentiontotreat
popul
treatment
group
compar
use
generalis
linear
model
statist
signific
set
p
account
multipl
comparison
trial
regist
australian
new
zealand
clinic
trial
registri
complet
find
april
march
children
screen
enrol
juli
june
children
alloc
start
exacerb
amoxicillinclavulan
group
azithromycin
group
placebo
group
respiratori
virus
identifi
children
avail
nasal
swab
day
treatment
primari
outcom
data
avail
children
one
child
miss
data
placebo
group
record
nonresolv
accord
criteria
defin
priori
day
exacerb
resolv
children
amoxicillinclavulan
group
azithromycin
group
placebo
group
compar
placebo
rel
risk
resolut
day
ci
numberneededtotreat
nnt
ci
amoxicillinclavulan
group
nnt
azithromycin
group
advers
event
record
children
amoxicillinclavulan
group
azithromycin
group
placebo
group
event
sever
lifethreaten
interpret
amoxicillinclavulan
treatment
benefici
term
resolut
nonsever
exacerb
bronchiectasi
children
remain
firstlin
oral
antibiot
set
although
bronchiectasi
major
contributor
chronic
respiratori
morbid
mortal
global
randomis
control
trial
rct
done
guid
manag
bronchiectasi
characteris
acut
respiratori
exacerb
children
associ
increas
parent
stress
impair
qualiti
life
lung
function
declin
sever
exacerb
requir
hospitalis
bronchiectasi
guidelin
advis
treat
exac
bation
antibiot
day
predomin
pathogen
detect
lower
airway
children
bronchiectasi
haemophilu
influenza
strepto
coccu
pneumonia
moraxella
catarrhali
wherea
unlik
cystic
fibrosi
pseudomona
aeruginosa
uncommon
accordingli
combin
australian
new
zealand
guidelin
bronchiectasi
children
adult
recommend
amoxicillinclavulan
empir
firstlin
oral
antibiot
nonsever
exacerb
british
thorac
societi
guidelin
bronchiectasi
adult
also
recommend
use
oral
amoxicillin
amoxicillinclavulan
exacerb
adult
highlight
absenc
randomis
placebo
control
trial
likewis
latest
european
adult
guidelin
refer
earlier
public
amoxicillinclavulan
recommend
first
option
acut
exacerb
patient
without
p
aeruginosa
infect
young
children
often
unabl
expector
provid
reliabl
lower
airway
specimen
amoxicillinclavulan
usual
continu
whole
treatment
cours
nevertheless
azithromycin
broad
antimicrobi
spectrum
conveni
oncedaili
dose
becom
popular
altern
amoxicillinclavulan
inde
region
australia
children
undergo
bronchoscopi
chronic
cough
receiv
azithromycin
preced
period
previou
rct
show
day
treatment
oral
azithromycin
noninferior
within
margin
amoxicillinclavulan
manag
nonsever
nonhospitalis
exacerb
children
bronchiectasi
howev
receiv
azithromycin
took
significantli
longer
median
differ
day
achiev
symptom
resolut
although
azithromycin
noninferior
amoxicillinclavulan
superior
rct
compar
either
antibiot
placebo
done
address
import
clinic
question
whether
oral
antibiot
necessari
treat
nonsever
acut
exacerb
bronchiectasi
role
antibiot
manag
exac
bation
sever
also
question
expert
suggest
exacerb
trigger
virus
might
selflimit
children
almost
half
acut
exacerb
associ
virus
antimicrobi
resist
increas
global
concern
import
determin
efficaci
antibiot
treat
exacerb
thu
absenc
publish
randomis
placebocontrol
trial
oral
antibiot
either
children
adult
acut
exacerb
bronchiectasi
aim
test
whether
two
commonli
use
differ
class
oral
antibiot
name
amoxicillinclavulan
azithromycin
superior
placebo
achiev
resolut
nonsever
exacerb
day
treatment
secondari
aim
assess
effect
antibiot
exacerb
durat
time
next
respiratori
exacerb
parent
coughspecif
qualityoflif
pcqol
score
system
inflammatori
marker
spirometri
upper
airway
microbiolog
treatmentrel
advers
effect
well
describ
evid
studi
start
studi
search
pubm
cochran
databas
randomis
control
trial
rct
involv
bronchiectasi
publish
incept
jan
use
search
term
bronchiectasi
placebo
control
trial
search
use
keyword
antibiot
bronchiectasi
randomis
exacerb
databas
search
restrict
report
english
identifi
six
rct
investig
antibiot
treatment
exacerb
adult
one
use
inhal
gentamicin
placebocontrol
small
sampl
size
three
openlabel
five
compar
either
differ
antibiot
differ
dose
agent
none
involv
macrolid
antibiot
children
studi
period
publish
result
parallel
studi
show
within
margin
azithromycin
noninferior
amoxicillinclavulan
achiev
symptom
resolut
day
treat
acut
exacerb
bronchiectasi
episod
took
significantli
longer
resolv
azithromycin
amoxicillinclavulan
randomis
placebocontrol
trial
assess
treatment
exacerb
bronchiectasi
children
still
lack
knowledg
first
rct
compar
use
oral
antibiot
placebo
treat
exacerb
patient
bronchiectasi
unrel
cystic
fibrosi
threearm
rct
amoxicillinclavulan
show
benefit
compar
placebo
achiev
symptom
resolut
within
day
nonsever
nonhospitalis
acut
exacerb
bronchiectasi
children
exacerb
resolut
slightli
nonsignificantli
frequent
azithromycin
group
placebo
group
compar
placebo
azithromycin
treatment
associ
increas
proport
azithromycinresist
bacteria
isol
nasopharynx
evid
studi
support
recommend
use
amoxicillinclavulan
treatment
exacerb
bronchiectasi
children
taken
togeth
previous
publish
noninferior
rct
compar
amoxicillinclavulan
azithromycin
amoxicillinclavulan
remain
firstlin
antibiot
treatment
nonsever
exacerb
bronchiectasi
children
azithromycin
could
reserv
use
select
set
patient
genuin
penicillin
hypersensit
situat
less
frequent
supervis
dose
might
overcom
difficulti
adher
point
preval
respiratori
virus
atyp
bacteri
pathogen
exacerb
threearm
parallelgroup
doubledummi
doubl
blind
placebocontrol
intervent
rct
done
four
paediatr
centr
australia
brisban
darwin
perth
new
zealand
auckland
children
age
year
attend
one
four
paediatr
centr
elig
enrol
ctconfirm
bronchiectasi
diagnos
respiratori
physician
year
immedi
studi
entri
diagnos
earlier
follow
regularli
respiratori
physician
treatment
bronchiectasi
least
two
respiratori
exacerb
month
studi
entri
exclus
criteria
includ
cystic
fibrosi
liver
dy
function
hypersensit
macrolid
antibiot
enrol
previous
rct
patient
also
exclud
time
randomis
sever
exacerb
bronchiectasi
dyspnoea
hypoxia
oxygen
satur
air
hospitalis
within
preced
week
p
aeruginosa
detect
within
previou
week
ever
nontubercul
mycobacteri
infect
receiv
macrolid
antibiot
within
previou
week
receiv
treatment
cancer
take
oral
nonmacrolid
antibiot
longterm
basi
week
bronchiectasi
exclud
antibiot
ceas
tempor
arili
patient
receiv
studi
medic
written
inform
consent
obtain
parent
caregiv
written
assent
obtain
children
older
year
human
research
ethic
committe
particip
site
approv
trial
monitor
independ
datamonitor
committe
studi
protocol
publish
previous
randomis
stratifi
centr
age
year
year
aetiolog
bronchiectasi
patient
postinfecti
idiopath
diseas
diseas
relat
immunodefici
aspir
primari
ciliari
dyskinesia
caus
comput
gener
permutedblock
block
size
random
isat
alloc
sequenc
prepar
central
independ
statistician
use
alloc
children
one
three
group
amoxicillinclavulan
group
azithromycin
group
placebo
group
respiratori
physician
research
assist
site
respons
enrol
time
exacerb
child
alloc
next
number
stratifi
randomis
list
maintain
local
hospit
pharmacist
extern
studi
statistician
trial
pharmacist
involv
data
collect
conduct
studi
sequenc
prepar
alloc
alloc
conceal
investig
particip
done
central
countri
particip
caregiv
studi
coordin
variou
site
investig
mask
treatment
assign
data
analysi
complet
doubledummi
trial
particip
receiv
either
one
activ
studi
medic
equival
volum
placebo
studi
medic
placebo
studi
medic
placebo
medic
institut
drug
technolog
melbourn
australia
indistinguish
appear
tast
respect
activ
antibiot
parent
caregiv
enrol
children
instruct
contact
research
staff
child
exacerb
acut
exacerb
confirm
children
randomli
alloc
studi
group
studi
medic
suppli
dri
powder
reconstitut
home
ident
instruct
prepar
activ
medic
match
placebo
ad
equal
volum
water
studi
medic
children
amoxicillinclavulan
group
receiv
oral
suspens
amoxicillinclavulan
mgkg
per
day
maximum
mg
divid
twice
daili
dose
placebo
azithromycin
daili
azithromycin
group
receiv
azithromycin
mgkg
per
day
maximum
mg
oncedaili
dose
placebo
amoxicillinclavulan
twice
daili
placebo
group
receiv
placebo
medic
treatment
cours
last
day
align
local
intern
guidelin
follow
consult
respiratori
physician
colleagu
feedback
parent
day
longest
period
deem
accept
treat
exacerb
placebo
safeti
exit
day
appendix
p
adher
assess
return
studi
medic
bottl
review
cough
score
advers
event
diari
exacerb
includ
resolut
failur
respond
studi
medic
predefin
per
previou
studi
rct
baselin
state
child
ascertain
enrol
use
valid
cough
diari
card
clinic
examin
nonsever
exacerb
defin
increas
cough
frequenc
chang
charact
cough
ie
dri
wet
increas
sputum
volum
purul
least
consecut
day
without
accompani
dyspnoea
hypoxia
oxygen
satur
air
need
hospitalis
accord
treat
clinician
exacerb
consid
resolv
cough
score
return
baselin
least
consecut
day
randomis
commenc
studi
medic
new
symptom
associ
episod
fever
see
onlin
appendix
lethargi
gener
malais
resolv
exacerb
consid
resolv
even
child
exit
studi
protocol
reason
resolut
treatment
consid
fail
cough
score
return
baselin
least
consecut
day
day
randomis
commenc
studi
medic
also
associ
new
symptom
resolv
children
treat
openlabel
amoxicillinclavulan
unless
judg
respiratori
physician
requir
intraven
antibiot
treatment
failur
also
record
children
whose
resolut
statu
unknown
exacerb
confirm
medic
review
clinic
outreach
clinic
home
visit
day
treatment
famili
telephon
research
staff
monitor
progress
children
review
clinic
day
resolut
exacerb
day
resolut
ascertain
examin
cough
symptom
diari
record
prospect
remot
rural
area
home
visit
alway
feasibl
studi
medic
pcqol
questionnair
sent
via
express
post
parent
caregiv
complet
daili
cough
symptom
diari
receiv
studi
medic
children
follow
monthli
phone
call
research
staff
month
exacerb
next
exacerb
finish
studi
medic
whichev
earlier
addit
record
cough
diari
card
enrol
baselin
pcqol
questionnair
complet
oxygen
satur
measur
blood
drawn
assess
white
blood
cell
count
creactiv
protein
concen
tration
children
age
year
older
underw
spirometri
fev
predict
record
accord
current
guidelin
possibl
determin
clinic
set
test
repeat
day
treatment
exacerb
nasal
swab
collect
day
treatment
exacerb
cultur
respiratori
bacteri
pathogen
underw
antibiot
suscept
test
describ
previous
nasal
swab
also
underw
realtim
pcr
assay
use
establish
method
detect
atyp
bacteria
mycoplasma
pneumonia
chlamydia
pneumonia
differ
virus
respiratori
syncyti
virus
subtyp
b
adenovirus
influenza
b
virus
human
parainfluenza
viru
type
human
metapneumoviru
human
coronavirus
type
picornavirus
rhinoviru
enteroviru
human
bocaviru
human
polyomavirus
ki
wu
children
alloc
receiv
amoxicillinclavulan
azithromycin
compar
placebo
group
primari
outcom
proport
children
whose
exacerb
resolv
day
intentiontotreat
popul
prespecifi
secondari
outcom
exacerb
durat
time
next
respiratori
exacerb
day
date
resolut
receiv
studi
medic
begin
next
exacerb
calcul
children
whose
exacerb
resolv
day
chang
pcqol
score
biomark
system
inflamm
white
blood
cell
count
creactiv
protein
concentr
fev
predict
nasal
carriag
respiratori
bacteri
pathogen
includ
antibiot
resist
treatment
day
respiratori
virus
atyp
bacteria
treatment
day
treatmentrel
advers
effect
time
next
respiratori
exacerb
day
patient
calcul
day
exacerb
resolv
receiv
studi
medic
secondari
analys
done
intentionto
treat
popul
perprotocol
analys
also
done
post
hoc
analysi
base
age
group
year
year
viru
identifi
day
treatment
exacerb
present
absent
primari
secondari
outcom
sampl
size
base
pilot
studi
compar
oral
amoxicillinclavulan
azithromycin
placebo
term
resolut
day
assum
exacerb
would
resolv
day
receiv
antibiot
versu
placebo
group
set
account
two
twosid
primari
comparison
interim
analysi
sampl
size
per
group
estim
provid
power
detect
differ
primari
outcom
statist
analysi
plan
approv
studi
investig
independ
datamonitor
committe
data
analys
data
also
analys
group
alloc
reveal
interim
analysi
done
independ
research
anticip
sampl
size
achiev
independ
datamonitor
committe
deem
interim
result
meet
predetermin
stop
criteria
use
intentiontotreat
prespecifi
perprotocol
analys
appendix
pp
site
age
caus
bronchiectasi
includ
analys
factor
part
protocol
statist
analysi
plan
previou
studi
use
stratif
randomis
allow
balanc
three
group
present
summari
statist
median
iqr
continu
data
frequenc
categor
data
associ
treatment
group
resolut
exacerb
investig
use
generalis
linear
regress
model
binomi
famili
log
link
report
rel
risk
rr
ci
numberneededtotreat
benefit
nnt
calcul
generalis
linear
model
binomi
famili
ident
link
model
treatment
group
includ
main
effect
covari
includ
associ
treatment
group
exacerb
durat
treatment
group
time
next
exacerb
investig
use
median
regress
children
whose
exacerb
resolv
day
receiv
openlabel
amoxicillinclavulan
includ
analys
children
exacerb
censor
day
month
total
durat
followup
associ
treatment
group
chang
secondari
outcom
treatment
day
also
investig
use
median
regress
associ
treatment
group
microbiolog
result
assess
test
bacteriolog
result
also
use
generalis
linear
model
binomi
famili
ident
link
estim
risk
differ
control
baselin
bacteri
preval
appendix
pp
posthoc
analys
base
age
group
presenc
virus
atyp
bacteria
also
done
report
appendix
pp
data
analys
stata
version
addit
detail
studi
method
describ
appendix
pp
studi
regist
intern
standard
rct
australian
new
zealand
clinic
trial
registri
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
vg
abc
mjb
rsw
access
raw
data
correspond
author
full
access
data
studi
final
respons
decis
submit
public
april
march
children
screen
enrol
children
children
discontinu
studi
medic
hospitalis
treat
oral
amoxicillinclavulan
per
studi
protocol
except
one
child
amoxicillin
clavulan
group
given
sulfamethoxazoletrimethoprim
respiratori
physician
one
child
azithromycin
group
prescrib
roxithromycin
respiratori
physician
characterist
baselin
higher
rate
resolut
amoxicillinclavulan
group
formal
stati
tical
signific
per
apriori
definit
account
use
placebo
group
comparison
amoxicillinclavulan
group
azithromycin
group
well
interim
analysi
azithromycin
group
exacerb
resolv
day
children
rr
resolut
vs
placebo
nnt
although
differ
meet
predefin
signific
threshold
median
durat
exacerb
placebo
group
day
iqr
longer
amoxicillinclavulan
group
day
differ
significantli
azithromycin
group
day
median
time
next
exacerb
resolut
similar
three
group
day
placebo
group
day
vs
placebo
amoxicillinclavulan
group
day
vs
placebo
azithromycin
group
appendix
p
chang
pcqol
score
white
blood
cell
count
creactiv
protein
concentr
differ
significantli
placebo
group
either
tabl
spirometri
begin
treatment
done
particip
studi
particip
age
less
year
particip
live
remot
site
children
research
staff
carri
spirometri
equip
home
visit
requir
pair
spirometri
result
day
treatment
avail
children
fev
predict
valu
show
significantli
greater
improv
day
day
amoxicillinclavulan
group
placebo
group
although
particip
number
provid
data
small
tabl
day
chang
fev
predict
valu
differ
significantli
azithromycin
placebo
group
tabl
pair
nasal
swab
avail
analysi
signific
betweengroup
differ
observ
bacteria
isol
treatment
day
howev
day
potenti
pathogen
bacteria
isol
nasopharynx
significantli
fewer
patient
amoxicillinclavulan
p
azithromycin
p
group
placebo
group
tabl
azithromycin
group
proport
azithromycin
resist
bacteri
isol
increas
day
two
patient
pathogen
bacteri
isol
day
five
eight
wherea
proport
antibioticresist
bacteria
chang
substanti
day
amoxicillinclavulan
placebo
group
children
azithromycinresist
bacteri
pathogen
day
prescrib
azithromycin
previous
respect
respiratori
physician
respiratori
virus
detect
pcr
children
avail
nasal
swab
day
treatment
tabl
appendix
p
one
child
three
virus
identifi
anoth
children
two
virus
detect
singl
viru
identifi
nasal
swab
specimen
c
pneumonia
bacteria
detect
pcr
nasal
swab
five
children
two
virus
codetect
pneumonia
bacteria
detect
three
children
one
also
viru
co
detect
rhinoviru
common
viru
detect
children
virus
identifi
children
avail
nasal
swab
respiratori
virus
detect
significantli
higher
proport
particip
day
antibiot
treatment
group
placebo
group
nasal
swab
amoxicillinclavulan
group
vs
placebo
azithromycin
group
vs
placebo
placebo
group
howev
rel
distribut
viru
type
similar
across
three
group
although
except
rhinovirus
number
individu
viru
type
detect
small
appendix
p
one
child
azithromycin
group
exit
studi
day
treatment
one
placebo
group
exit
day
medic
refus
eight
children
stop
studi
medic
receiv
openlabel
antibiot
gastrointestin
advers
event
three
amoxicillinclavulan
group
three
azithromycin
group
two
placebo
group
eight
well
two
refus
medic
receiv
openlabel
amoxicillinclavulan
per
studi
protocol
one
child
three
group
hospitalis
worsen
symptom
one
receiv
azithromycin
hospitalis
seizur
figur
tabl
perprotocol
analysi
primari
secondari
outcom
appendix
pp
well
posthoc
analysi
basi
age
group
year
year
viru
identifi
day
treatment
exacerb
present
absent
primari
secondari
outcom
adjust
data
minor
imbal
group
nasal
swab
bacteria
baselin
also
present
appendix
pp
result
perprotocol
analys
similar
intentiontotreat
analys
primari
secondari
outcom
data
median
iqr
nn
pcqolpar
coughspecif
qualityoflif
children
seen
studi
doctor
day
treatment
exacerb
incomplet
inform
includ
blood
sampl
unabl
undergo
spirometri
result
studi
show
use
oral
amoxicillinclavulan
day
nonsever
exacerb
bronchiectasi
children
superior
placebo
achiev
exacerb
resolut
end
treatment
decreas
durat
exacerb
outcom
azithromycin
associ
improv
meet
prespecifi
margin
statist
signific
superior
placebo
betweengroup
differ
observ
time
next
exacerb
pcqol
score
inflammatori
marker
creactiv
protein
concentr
white
blood
cell
count
adher
highest
amoxicillinclavulan
group
antibiot
well
toler
although
antibiot
reduc
overal
presenc
bacteri
pathogen
nasopharynx
day
compar
placebo
proport
bacteri
isol
antibiot
resist
significantli
increas
azithromycin
group
amoxicillinclavulan
group
compar
placebo
end
treatment
overal
particip
avail
nasal
swab
respiratori
virus
detect
begin
exacerb
adult
bronchiectasi
antibiot
treatment
reduc
airway
system
inflamm
sputum
volum
purul
bacteri
densiti
improv
symptom
antibiot
consid
crucial
inter
vention
treatment
bronchiectasi
absenc
rctlevel
evid
either
children
adult
placebocontrol
trial
provid
evid
confirm
recommend
use
oral
amoxicillinclavulan
treat
nonsever
exacerb
bronchiectasi
children
superior
amoxicillinclavulan
placebo
achiev
cough
resolut
nnt
ci
decreas
exacerb
durat
consist
result
previou
rct
also
describ
efficaci
amoxicillinclavulan
compar
placebo
treat
chronic
wet
cough
children
suspect
protract
bacteri
bronchiti
studi
show
result
week
similar
regard
achiev
cough
resolut
nnt
best
knowledg
compar
paediatr
studi
done
date
rct
adult
moder
exacerb
mildtomoder
chronic
obstruct
pulmonari
diseas
copd
show
day
amoxicillinclavulan
effect
placebo
absolut
differ
proport
cure
ci
nnt
howev
nnt
valu
suggest
although
amoxicillinclavulan
efficaci
antibiot
alway
need
achiev
resolut
exacerb
bronchiectasisan
observ
report
previous
adult
copd
thu
studi
identifi
children
bronchiectasi
exacerb
like
benefit
antibiot
need
contrast
oral
amoxicillinclavulan
azithromycin
recommend
firstlin
agent
treat
non
sever
exacerb
bronchiectasi
nonetheless
includ
antibiot
rct
commonli
use
set
treatment
adher
problemat
although
proport
children
treatment
resolut
median
length
exacerb
similar
amoxicillinclavulan
resolut
durat
day
azithromycin
day
group
differ
azithromycin
placebo
formal
statist
signific
howev
durat
exacerb
could
meaning
calcul
whose
exacerb
resolv
day
children
exit
studi
protocol
achiev
resolut
given
openlabel
antibiot
per
studi
protocol
includ
analysi
would
thu
reflect
true
effect
intervent
number
children
resolut
placebo
group
significantli
lower
antibiot
group
previou
rct
show
although
week
oral
azithromycin
treatment
noninferior
within
margin
week
oral
amoxicillinclavulan
achiev
symptom
resolut
day
children
nonsever
exacerb
bronchiectasi
episod
durat
significantli
shorter
children
alloc
receiv
amoxicillinclavulan
median
durat
day
iqr
compar
azithromycin
day
differ
durat
clinic
signific
stress
anxieti
loss
work
parent
associ
bronchiectasi
exacerb
never
theless
current
studi
compar
placebo
antibiot
day
similar
effect
size
respect
symptom
resolut
episod
durat
inde
p
valu
compar
azithromycin
placebo
suggest
statist
signific
might
achiev
twoarm
comparison
azithromycin
placebo
ie
without
need
adjust
multipl
comparison
furthermor
given
higher
thananticip
proport
particip
achiev
resolut
placebo
group
possibl
studi
insuffici
power
show
statist
superior
azithromycin
taken
togeth
previou
rct
support
empir
use
amoxicillinclavulan
treatment
firstlin
antibiot
choic
nonsever
exacerb
bronchiectasi
children
furthermor
data
studi
indic
azithro
mycin
increas
proport
azithromycinresist
bacteria
nasopharynx
recognis
reser
voir
transmiss
antibioticresist
organ
rct
addit
limit
first
dose
antibiot
might
optimum
dose
use
clinic
practic
use
mgkg
per
day
amoxicillinclavulan
formul
although
mgkg
per
day
amoxicillin
recommend
treat
childhood
pneumonia
set
although
higher
daili
dose
mgkg
day
use
preschoolag
children
acut
wheez
ill
second
data
secondari
outcom
avail
children
pair
pcqol
data
avail
children
amoxicillinclavulan
azithromycin
placebo
group
howev
pair
pcqol
data
least
children
group
base
betweengroup
differ
point
minimum
import
differ
provid
power
addit
pair
blood
result
spirometri
data
avail
small
proport
children
group
although
improv
fev
predict
valu
differ
significantli
amoxicillinclavulan
group
compar
placebo
group
small
sampl
mean
result
must
interpret
cautious
third
higherthanexpect
proport
children
spontan
resolut
placebo
group
might
reflect
milder
natur
exacerb
group
versu
two
antibiot
group
could
directli
relat
lower
preval
respiratori
virus
begin
exacerb
placebo
group
compar
group
studi
virusassoci
exacerb
known
sever
like
necessit
intraven
antibiot
hospitalis
respiratori
virus
detect
placebo
group
median
durat
exacerb
day
virusposit
group
day
viru
neg
group
appendix
pp
although
explain
increas
viral
presenc
antibiot
group
compar
placebo
group
baselin
paramet
exacerb
similar
among
three
group
tabl
role
virus
nonsever
bronchiectasi
exacerb
explor
studi
need
identifi
subset
nonsever
exacerb
might
resolv
without
antibiot
plan
evalu
explor
variou
clinic
microbiolog
factor
associ
resolut
exacerb
final
although
deep
nasal
swab
directli
reflect
lower
airway
microbiolog
use
ascertain
effect
antibiot
carriag
resist
bacteri
respiratori
pathogen
site
princip
reservoir
spread
antibiot
resist
respiratori
bacteria
within
commun
pair
nasal
swab
bacteri
cultur
avail
less
children
although
number
children
macrolideresist
pathogen
similar
placebo
azithromycin
group
day
proport
increas
carriag
macrolideresist
pathogen
azithromycin
group
signific
conclus
randomis
placebocontrol
trial
show
nonsever
exacerb
bronchi
ectasi
children
oral
amoxicillinclavulan
superior
placebo
day
treatment
term
achiev
symptom
resolut
shorten
exac
bation
durat
azithromycin
associ
improv
exacerb
resolut
durat
compar
placebo
meet
threshold
signific
defin
threearm
trial
importantli
azithromycin
also
associ
increas
proport
bacteria
azithromycin
resist
compar
placebo
result
suggest
amoxicillinclavulan
remain
firstlin
oral
antibiot
treatment
nonsever
exacerb
bronchiectasi
children
oncedaili
azithromycin
reserv
genuin
penicillin
hypersensit
situat
directli
observ
therapi
feasibl
set
poor
treatment
adher
abc
conceiv
studi
abc
psm
kg
kafo
g
pjt
mc
particip
studi
design
vg
abc
psm
cab
ibm
hmb
activ
recruit
particip
vg
gbm
particip
coordin
data
acquisit
ac
randomli
alloc
patient
pharmaci
dispens
medic
vg
particip
coordin
followup
statist
analysi
hsv
develop
protocol
process
nasal
swab
bacteri
result
vg
abc
mjb
rsw
access
raw
data
rsw
supervis
statist
analys
vg
draft
initi
manuscript
substanti
revis
undertaken
abc
kg
author
contribut
edit
manuscript
approv
final
version
declar
compet
interest
protocol
studi
publish
previous
per
institut
polici
involv
indigen
children
australia
new
zealand
accord
nation
guidelin
unabl
share
individu
particip
data
other
specif
consent
obtain
statist
analysi
plan
made
avail
upon
individu
request
correspond
author
